申请人:Escient Pharmaceuticals, Inc.
公开号:US20210340106A1
公开(公告)日:2021-11-04
Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):
or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R
1
, R
2
and R
3
are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.